



# A NEW ERA IN **MASH**

How Disease-Specific  
Therapies Are  
Changing the Game  
and Best Practices for  
Clinical Integration

## **Nonalcoholic Steatohepatitis (NASH) vs Metabolic Dysfunction-Associated Steatohepatitis (MASH)**

- The following presentation contains a discussion of an FDA-approved drug for the treatment of NASH
- NASH is now known as MASH to emphasize the underlying pathophysiology of this liver condition
- Presenters may use NASH and MASH interchangeably

# Faculty



**Michael Roden, MD**

Professor and Chair of Endocrinology  
and Metabolic Diseases  
Heinrich-Heine University  
Director of the Deutsches Diabetes Zentrum  
Director of the University Hospital  
Düsseldorf's  
Division of Endocrinology and Diabetology  
Düsseldorf, Germany



**Amalia Gastaldelli, PhD**

Director of Research,  
Head of the Metabolic Diseases Group  
and of the Multi-Omics Mass  
Spectrometry Lab  
Institute of Clinical Physiology, CNR  
Pisa, Italy



**Michael Trauner, MD**

Professor of Medicine  
Chair, Division of Gastroenterology and  
Hepatology  
Department of Internal Medicine III  
Medical University of Vienna  
Vienna, Austria

# Overview and Target Audience

**This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.**

**This activity is supported by an educational grant from Madrigal Pharmaceuticals.**

**ACTIVITY OVERVIEW** – Addressing disease progression in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) has long been hindered by the absence of targeted therapies. With the approval and late-stage development of agents featuring novel mechanisms of action, a new era of disease management is here. This activity will showcase clinical integration of thyroid hormone receptor- $\beta$  (THR- $\beta$ ) agonists through interactive, case-based discussions. The most recent advances in noninvasive testing to better detect liver disease along with clinical efficacy and safety data of late-stage therapies will also be discussed.

**TARGET AUDIENCE** – This initiative is intended for endocrinology, diabetology, cardiology, and hepatology health care providers, as well as other specialty clinicians involved in the management of patients with MASLD/MASH.

## Learning Objectives

Upon successful completion of this activity, participants should be better able to:

- **Describe** the mechanistic and clinical rationale for THR- $\beta$  agonists as a means of treating MASLD/MASH
- **Evaluate** the evidence on THR- $\beta$  agonists, and other disease-specific therapy classes, considering efficacy, safety/tolerability, and PROs
- **Identify** best practices for facilitating and documenting an accurate, non-invasive, and timely diagnosis of MASLD/MASH to support access to disease-specific therapy
- **Develop** guideline-aligned management paradigms for MASLD/MASH that incorporate pharmacotherapy tailored to individual clinical scenarios

# Agenda

**Introduction. The Growing Burden of MASLD/MASH: A Call to Action, New Treatments are Coming**

*Michael Roden, MD*

**Need to Improve Screening and Diagnosis in Patients with Diabetes**

*Michael Trauner, MD*

**Changing the MASH Paradigm with THR- $\beta$  Agonists and Other Disease-specific Therapies**

*Amalia Gastaldelli, PhD*

**Integrating MASLD/MASH-Specific Therapy into Guideline-Aligned Real-World Practice**

*All Faculty*

**Conclusions and Q&A**

*All Faculty*

# Accreditation & Credit Designation Statements

## Criteria for Success

Certificates of completion will be awarded based on the participant's attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [tbrignoni@akhcme.com](mailto:tbrignoni@akhcme.com).



Credit provided by AKH Inc., Advancing Knowledge in Healthcare



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Type of Activity:** Application-based

**Fee Information:** There is no fee for this educational activity

# Disclosures

## Disclosure

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

**Michael Roden, MD**, has disclosed the following relevant financial relationships: Advisor - AstraZeneca, Echosens, Novo Nordisk and Pfizer; Consultant - AstraZeneca, Echosens, Novo Nordisk and Pfizer; Researcher - Boehringer-Ingelheim, Nutricia/Danone, Sanofi-Aventis

**Michael Trauner, MD**, has disclosed the following relevant financial relationships: Advisor - AbbVie, Albireo, Agomab, Boehringer Ingelheim, Chemomab, Falk, Gilead, Genfit, Hightide, Intercept, Ipsen, Jannsen, Mirum, Novartis, Pliant, ProQR Therapeutics, Rectify; Ownership interest - Co-inventor (service invention) for patents on medical use of norUDCA (filed by the Medical Universities of Graz and Vienna); Researcher - Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, Ultrademyx; Speaker - Albireo, Falk Foundation, Gilead, Intercept, Ipsen, Madrigal

**Amalia Gastaldelli, PhD**, has disclosed the following relevant financial relationships: Researcher - Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk, Madrigal, Pfizer, Regeneron

## STAFF/REVIEWERS

Louis Settembrino, CHCP, Catalyst Medical Education, LLC, President and CEO: has disclosed no financial relationships.

Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.

Trish Brignoni, AKH Director Operations & Compliance, has no financial relationships to disclose.

Stephanie S. Wenick, MPhil, Medical Writer, has served as a consultant medical writer for Nanoscope Therapeutics, Inc.

AKH and Catalyst Medical Education, LLC Planners and Reviewers, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

## **Disclaimer**

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [optout@akhcme.com](mailto:optout@akhcme.com) with your information with "Opt Out" in the subject line.

## **Disclosure of Unlabeled Use and Investigational Product**

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.